Effectivenes of spironolacton in complex therapy of rheumatoid arthritis

Title:

Effectivenes of spironolacton in complex therapy of rheumatoid arthritis
Effectivenes of spironolacton in complex therapy of rheumatoid arthritis

Creator:

Komarova, Elena and Rebrov, Borys

Contributor:

Komarova, Elena and Rebrov, Borys

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:bmc15010743-bf45c1ed-0ada-4215-9dff-04d4855a5a5f
uuid:bmc15010743-bf45c1ed-0ada-4215-9dff-04d4855a5a5f
local:bmc15010743
http://ojs.journals.cz/index.php/EMHPJ/issue/archive
isrc: xxx
local: bmc15010743

Subject:

revmatoidní artritida--diagnóza--etiologie--farmakoterapie, antagonisté mineralokortikoidních receptorů--terapeutické užití, spironolakton--terapeutické užití, výsledek terapie, kvalita života, cytokiny--účinky léků, kohortové studie, statistika jako téma, dospělí, ženské pohlaví, lidé, mužské pohlaví, and lidé středního věku

Type:

model:article, article, Text, srovnávací studie, and TEXT

Format:

electronic, electronic resource, remote, and elektronický zdroj

Description:

Aldosterone blocker Spironolactone has anti­inflammatory, anti­proliferative and anti­oxidative effects, that is why pathogenetically it is expedient to use it in complex therapy of rheumatoid arthritis. Material and methods: 46 patients with RA took 25­50 mg/day of Spironolactone during 12 months as an addition to standard therapy, the comparison group consisted of 47 patients that got only standard therapy, all the patients were fully examined prior and post the treatment. Results: complex RA therapy leads to improved VAS, HAQ, the antioxidative potential index F; decreased blood concentrations of TNF­α, ICAM­1, FGF and VEGF in contrast to standard therapy. Complex therapy made reduced the DAS 28 more > 0.6. Conclusions: applying of Spironolactone in complex therapy of rheumatoid arthritis contributes to more pronounced improvement in indices of articular syndrome and patients life quality, reduce of anti­inflammatory, anti­proliferative and angiogenic cytokines, and more effectively reduces the activity of the disease comparing to standard therapy., Elena Komarova, Borys Rebrov, and Literatura

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Relation:

European medical, health and pharmaceutical journal--MED00177703

Source:

European medical, health and pharmaceutical journal : open access reviewed journal | 2014 Volume:7 | Number:1

Harvested from:

CDK

Metadata only:

false

Date:

2014